Stock Markets April 27, 2026 07:21 AM

HawkEye 360 Seeks $2.42 Billion Valuation in U.S. IPO

Virginia-based space analytics company files to list on NYSE as market momentum returns

By Nina Shah
HawkEye 360 Seeks $2.42 Billion Valuation in U.S. IPO

HawkEye 360, a Herndon, Virginia-based space analytics firm, has filed for a U.S. initial public offering seeking up to $416 million and targeting a valuation of as much as $2.42 billion. The company plans to offer 16 million shares at $24 to $26 each and to list on the New York Stock Exchange under the symbol HAWK. The move comes as the IPO market shows renewed activity following early-2026 volatility and geopolitical tensions.

Key Points

  • HawkEye 360 is targeting a valuation of up to $2.42 billion in its planned U.S. IPO.
  • The company plans to raise up to $416 million via 16 million shares priced between $24 and $26 and to list on the NYSE under the symbol HAWK; this activity impacts the space-technology sector, the IPO market and investment banking services.
  • Market dynamics influencing the timing include early-2026 equity-market volatility and escalations in the Middle East, which have affected broader investor sentiment and IPO market activity.

April 27 - HawkEye 360 has set parameters for a U.S. initial public offering that would imply a valuation of up to $2.42 billion, the space analytics company disclosed on Monday.

The Herndon, Virginia-based business is seeking to raise up to $416 million through an offering of 16 million shares, with an indicated price range of $24 to $26 per share. If completed at the top of that range, the pro forma valuation would reach $2.42 billion.

HawkEye plans to have its shares listed on the New York Stock Exchange under the trading symbol "HAWK." The underwriting syndicate includes Goldman Sachs, Morgan Stanley, RBC Capital Markets and Jefferies, according to the filing.

Company filings and planned listing details come as activity in the U.S. initial public offering market appears to be picking up. Several larger firms have recently announced intentions to pursue listings in New York after a period of uneven equity performance and geopolitical developments earlier in 2026.

Market participants have noted that a confidential filing by Elon Musk's SpaceX earlier in the month could encourage other space-technology companies to advance their own public-market plans. That confidential filing was cited as a factor that may foster additional interest from space-focused firms in tapping public markets.

This filing positions HawkEye to access public equity capital while listing with a well-known group of underwriters. The proposed share count, price band and underwriting team are now public as the company moves through the standard IPO process.


Summary

  • HawkEye 360 is targeting up to a $2.42 billion valuation in its U.S. IPO.
  • The company aims to raise up to $416 million by offering 16 million shares at $24 to $26 each.
  • HawkEye intends to list on the NYSE under the symbol HAWK, with Goldman Sachs, Morgan Stanley, RBC Capital Markets and Jefferies as underwriters.

Context

The filing comes amid a resurgence of IPO activity in New York after early-2026 volatility in equity markets and escalations in the Middle East. The confidential filing by SpaceX earlier this month has been noted as a development that may encourage other space-sector companies to consider public listings.

Risks

  • Resurgence in IPO activity could be fragile given the early-2026 volatility in equity markets; this exposes deals in the equity capital markets to shifting investor appetite.
  • Geopolitical escalations in the Middle East cited in the filing history represent a source of uncertainty for market sentiment, potentially affecting demand for new listings in the space-technology and related sectors.

More from Stock Markets

Customers Bank Engages OpenAI Engineers to Automate Lending and Onboarding Apr 27, 2026 Compass Therapeutics Shares Collapse After Mixed COMPANION-002 Results Apr 27, 2026 FDA Grants Breakthrough Therapy Designation to TERN-701 for Certain Chronic Myeloid Leukemia Patients Apr 27, 2026 AbbVie Seeks FDA Clearance for Subcutaneous Induction Dosing of SKYRIZI in Crohn’s Disease Apr 27, 2026 HawkEye 360 Opens IPO Roadshow, Seeks Up to $416 Million Apr 27, 2026